We conducted a systematic review to evaluate the (1) feasibility and efficacy and (2) safety and cost effectiveness of continuous positive airway pressure (CPAP) therapy in low-and middle-income countries (LMIC). We searched the following electronic bibliographic databases-MEDLINE, Cochrane CENTRAL, CINAHL, EMBASE and WHOLIS-up to December 2014 and included all studies that enrolled neonates requiring CPAP therapy for any indication. We did not find any randomized trials from LMICs that have evaluated the efficacy of CPAP therapy. Pooled analysis of four observational studies showed 66% reduction in in-hospital mortality following CPAP in preterm neonates (odds ratio 0.34, 95% confidence interval (CI) 0.14 to 0.82). One study reported 50% reduction in the need for mechanical ventilation following the introduction of bubble CPAP (relative risk 0.5, 95% CI 0.37 to 0.66). The proportion of neonates who failed CPAP and required mechanical ventilation varied from 20 to 40% (eight studies). The incidence of air leaks varied from 0 to 7.2% (nine studies). One study reported a significant reduction in the cost of surfactant usage with the introduction of CPAP. Available evidence suggests that CPAP is a safe and effective mode of therapy in preterm neonates with respiratory distress in LMICs. It reduces the in-hospital mortality and the need for ventilation thereby minimizing the need for up-transfer to a referral hospital. But given the overall paucity of studies and the low quality evidence underscores the need for large high-quality studies on the safety, efficacy and cost effectiveness of CPAP therapy in these settings.
INTRODUCTION
Of the total 2.9 million neonates who die every year, nearly 1 million (35%) die of preterm birth complications. 1 Preterm neonates are not only at high risk of mortality but also are at risk for developing serious morbidities like respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis and infections.
Despite advances in neonatal intensive care, respiratory distress syndrome remains the single, most important cause of mortality among preterm neonates. 2 More than 50% of neonates born before 31 weeks of gestation develop respiratory distress syndrome, which is due to deficiency of pulmonary surfactant production. 3, 4 Despite the advent of effective prevention and management strategies such as antenatal steroids, exogenous surfactant therapy and newer ventilatory techniques, nearly 40% very-preterm neonates either die or develop bronchopulmonary dysplasia by 36 weeks postconceptional age. [5] [6] [7] Continuous positive airway pressure (CPAP), which refers to the application of continuous distending pressure in a spontaneously breathing neonate, increases the functional residual capacity of the lung resulting in better gas exchange. 8 CPAP has been shown to reduce the risk of mortality by 48% 6 and the need for surfactant and mechanical ventilation by about 50%. 9 In addition, the use of CPAP has been found to decrease hospital stay 10 and need for referrals and up-transfers to tertiary units, saving nearly $10 000 for every six neonates treated. 11 Altogether, these benefits have made CPAP the standard of care in managing sick preterm neonates with respiratory distress in high-income countries.
Yet, it still remains unclear whether the same benefits pertain to low-and middle-income countries (LMIC) where the availability of trained doctors and nursing staff, round the clock monitoring facilities, and optimal CPAP devices and interfaces is still suboptimal. The problem is compounded by difficulty in delivering CPAP in the delivery room/during transport, lack of blenders and pulse-oximeters, lack of blood gas analyzers, chest x-ray equipment and finally the cost issues. 12 Without optimal equipment and skilled manpower, it is likely that CPAP may not be as effective and possibly less safe in LMIC settings. On the other hand, the higher costs of exogenous surfactant therapy and newer sophisticated ventilators may make CPAP the way forward for managing respiratory distress in these settings.
The question can be answered only by examining available evidence on the use of CPAP from LMIC. Therefore, we planned a systematic review to evaluate the efficacy, safety, feasibility and cost effectiveness of introducing and implementing CPAP at both population and health facility level in LMIC. The findings of the review would provide the policy makers available information to guide the upscale of the intervention in different settings from LMIC.
METHODS

Objectives
The major objectives of this review were to assess the 1 feasibility and efficacy and 2 safety and cost effectiveness of CPAP therapy in preterm neonates from LMICs (Table 1) .
Types of studies For the first objective, we included both observational and interventional studies (randomized controlled trials and quasirandomized trials) from LMICs that had evaluated the use of CPAP in preterm neonates. For the second objective, we included all studies from LMICs that had reported the use of CPAP in neonates (including case series that reported complications following CPAP therapy).
Interventions
We included all studies that evaluated the use of CPAP therapy in eligible neonates.
Outcome measures and their definitions Table 1 provides the list of critical outcomes and their definitions.
Search methods for identification of studies We searched the following electronic bibliographic databases-MEDLINE, Cochrane CENTRAL, CINAHL, EMBASE and WHOLIS-up to December 2014. We used the following search terms for searching Medline-'continuous positive airway pressure', 'respiration, artificial', 'positive-pressure respiration' or the text words: 'continuous distending pressure', 'CPAP', 'CDAP', 'distending pressure', 'continuous positive transpulmonary pressure', 'continuous transpulmonary pressure', 'continuous inflating pressure', 'positive pressure', 'positive expiratory pressure', 'positive end expiratory pressure', 'PEEP') AND LMIC. Similar terms were used for searching the other databases-LILACS, Popline and BiblioMap.
The search terms for LMIC were adapted from the two systematic reviews on cost effective interventions in LMIC. 13, 14 No language restrictions were used and no studies were excluded on the basis of study design. All causes of respiratory distress were considered. We scanned the title and abstract of the retrieved citations to exclude those that were obviously irrelevant. We retrieved the full text of the remaining studies to identify the relevant articles. The reference lists of included articles were also searched.
Data extraction and management Data extraction was done using a data extraction form predesigned and tested by the authors. Two reviewers (AT and MJS) independently extracted the relevant information including the number of participants, the number of events, adjusted odds ratio (OR) and its 95% confidence interval (CI).
Given the types of studies expected to be included and the broad objectives of the review, we did not intend to do any quality assessment of the included studies or meta-analysis of the results.
Statistical analysis Meta-analysis was performed with user written programs on Stata 11.2 software (StataCorp, College Station, TX, USA). Pooled estimates of the outcome measures were calculated from the relative risks or OR and 95% CI of the individual studies by generic inverse variance method. We examined for heterogeneity among the included studies by inspecting the forest plots and quantifying the impact of heterogeneity using a measure of the degree of inconsistency in the studies' results (I 2 statistic). We intended to use the fixed-effect model if the I 2 statistic was o60%; if the I 2 statistic was 60% or more, we planned to use the random effects model provided no major causes for heterogeneity could be identified. Figure 1 depicts the number of studies identified by the literature search and the studies included after reviewing the title/abstract or the full text. The search strategy identified 645 records, of which 597 were excluded after scanning title and abstract. Among the remaining 48 studies, 22 were eligible for inclusion in the systematic review. Description of the included studies has been provided as and when applicable in the following sections.
RESULTS
Feasibility and efficacy
In-hospital/neonatal mortality. We did not identify any randomized trial that had compared the effect of CPAP with other methods such as oxygen by hood on neonatal mortality. We identified a total of 13 observational studies had reported the effect of CPAP therapy on in-hospital or neonatal mortality in preterm neonates (Table 2 ). These studies can be broadly categorized into three groups: time-series/comparison with historical controls, case-control studies ('typical' case-control or analysis of prospective data like a case-control study) and prospective observational studies of CPAP therapy. Proportion of neonates developing pulmonary air-leak, sepsis, local trauma, shock during CPAP therapy (i) Time series/comparison with historical controls: one study from Fiji evaluated mortality data from two time periods -18 months before and 18 months after the introduction of bubble CPAP (bCPAP). 15 In the former period, there were 79/1106 deaths (7.1%) while in the latter there were 74/1382 deaths (5.4%), suggesting a trend toward lower mortality (OR 0.74, 95% CI 0.52 to 1.03; P = 0.06).
(ii) Case-control studies: a retrospective chart review from South Africa found that the use of nasal CPAP was associated with lower mortality among very low birth weight neonates (16.7 vs 32.8%; OR 0.22, 0.08 to 0.63). 16 The confounding effect of other variables was, however, unclear. Another small study from South Africa reported a mortality of 18.2% (2/11) with CPAP as against 80% (8/10; OR 0.06, 0.004 to 0.66) for initial treatment of respiratory distress with head box oxygen, with no backup of mechanical ventilation in the unit. 17 One nonrandomized study from Malawi compared the effects of nasal CPAP with oxygen therapy by nasal cannulae. The study reported a significantly lower mortality in the CPAP group as compared with the control group (29.0 vs 56.0%; OR 0.32, 95% CI 0.12 to 0.83). 18 Another retrospective study from South Africa compared outcomes of neonates manages with CPAP as against invasive ventilation. 19 The reported mortality in the CPAP group (25%) was comparable to the group that received ventilation (39%). The authors remarked that mortality in neonates successfully managed with CPAP was 18% and this dropped to 9% after correcting for neonates who were not offered ventilation. (iii) Uncontrolled observational studies: the reported mortality rates range from 8 to 26.6% in neonates who received CPAP. [20] [21] [22] [23] [24] [25] [26] Pooled analysis of the four studies that provided complete data showed 66% reduction in in-hospital mortality following CPAP therapy in preterm neonates (OR 0.34, 95% CI 0.14 to 0.82; random-effects model; Figure 2 ).
Proportion of neonates who failed CPAP and required mechanical ventilation. Eight studies from LMIC settings had reported this outcome (Table 2) . 20, 22, 23, [27] [28] [29] [30] [31] Except two studies that reported a higher failure rate of 38% 27 and 40%, 31 other studies reported a failure of 20 to 25%. One study from India reported that the Institution of CPAP alone in all spontaneously breathing preterm neonates with respiratory distress syndrome and administration of surfactant to only those needing mechanical ventilation reduced the need for intubations and surfactant administration without affecting the outcome adversely. 20 One study had reported the need of referral of one neonate due to non availability of ventilator in the unit. 20 The other neonates who required mechanical ventilation as a primary mode (33/83; 39.7%) were managed in the same unit. A before-after study from a referral hospital in Fiji suggested a reduction in the need of mechanical ventilation with the use of CPAP. The introduction of bCPAP was associated with a 50 per cent reduction in the need for mechanical ventilation-from 113/1106 (10.2%) prior to bCPAP to 70/1382 (5.1%) after introduction of CPAP (relative risk 0.5, 95% CI 0.37 to 0.66). 15 Safety of implementation of CPAP therapy Nine studies (India 2, Brazil 1, Oman 1 and Malaysia 1, South Africa 2, Malawi 2) had commented on the incidence of air leaks (Table 3 ). Of these, seven reported no pneumothorax in neonates receiving CPAP therapy. 18, 23, 25, 26, 28, 31, 32 One study reported the development of pneumothorax in two neonates (2/56; 3.5%). Both the neonates did not require mechanical ventilation and were stabilised on CPAP. 30 In contrast, a study from Malaysia reported a relatively higher incidence of pneumothorax after the implementation of CPAP therapy (7/97; 7.2%). 27 Three studies from LMIC settings had reported the occurrence of nasal trauma after the institution of CPAP therapy. [32] [33] [34] The study by Rego suggested increased occurrence of hyperemia with one specific type nasal prongs. 32 The studies by Yong 33 and Nascimento 34 suggested that nasal injury was observed in nearly all neonates instituted on CPAP and the risk was related to the duration of CPAP therapy (Table 3 ). In the study by Nascimento, mild hyperemia was observed in 79.6% (117/147) neonates and bleeding in 19.7% (29/147) neonates. The study suggested that training and educational programs can improve the care of newborns who are on CPAP and can help prevent complications related to CPAP use. 34 Another single center study suggested the utility of silicone gel sheeting to reduce the incidence of nasal injury. 35 No study from LMIC had reported the proportion of neonates who developed shock after institution of CPAP therapy. Two studies from LMIC reported no association of retinopathy of prematurity and institution of CPAP therapy. 36, 37 Both these studies were retrospective single center studies (Table 3) .
Cost-effectiveness of CPAP therapy Cost per one neonatal death or ventilation averted. No study from LMIC had reported this outcome.
Cost to the health facility and family. One study from Fiji-a retrospective evaluation of prospectively collected data-had reported the cost to the health facility. 15 The study included only the costs of the machines. For 6 years before the introduction of bCPAP, the NICU had five ventilators: three Bear Cub, cost of $40 000 each; and two Servo3000, cost of $65 000 each. In May 2003, bCPAP was introduced. Equipment was purchased to provide bCPAP to two neonates at any one time. The costs were $6000 for each CPAP machine and $300 for circuitry. 15 We identified one study by Levesque on the impact of implementing five potentially better respiratory practices on neonatal outcomes and costs. 38 The implemented practices included the exclusive use of bCPAP, provision of bCPAP in the delivery room, strict intubation criteria and strict extubation criteria, and prolonged CPAP to avoid supplemental oxygen. The study reported that the non-personnel cost of care for neonates o33 weeks' gestation was similar during the first 12 weeks of hospitalization before and after the guideline was implemented. The percentage of hospitalization days spent with a 1:1 staffing ratio was also similar before and after implementation of the guideline. However, the specific cost for surfactant replacement therapy was significantly lower in the latter period. 38 The cost of the nine stationary and three portable bCPAP units was much lower than the estimated 2007 cost of replacing the nine out-ofwarranty ventilators with new basic model conventional ventilators ($19 500 for bCPAP vs $135 000 for ventilators).
DISCUSSION
CPAP has now become a standard of care for all preterm neonates with respiratory distress. Evidence from high-quality studies suggests significant survival advantage in preterm neonates with severe respiratory distress and managed with CPAP as compared with those managed with only oxygen. 9 But the evidence is based on studies from only high-income countries. In the absence of such evidence base from LMICs, one cannot be really sure about the efficacy and safety of CPAP therapy in LMIC settings.
We found a significant reduction in the risk of in-hospital mortality following introduction of CPAP therapy (Figure 2) . The pooled effect size (OR 0.34, 95% CI 0.14 to 0.82) suggested similar, if not better, beneficial effect when compared with that reported from high-income countries (relative risk 0.52, 95% CI 0.32 to 0.87). 9 Given the nature of studies-before and after and case-controlincluded in the present review, the quality of evidence is likely to be low. There is a need to generate more evidence on the efficacy of CPAP in preterm neonates from LMICs. It may not be ethical to do randomized studies on the effects of CPAP now but it is definitely possible to have large high-quality observational studies from these settings.
The current review suggested that implementation of CPAP therapy is feasible in level 2 to 3 NICUs of LMICs. Only 25 to 40% of preterm neonates receiving CPAP therapy required mechanical ventilation (and referral, if ventilation facilities not available). A recent systematic review, which suggested a reduction in mechanical ventilation by 30 to 50%, had included studies of neonates managed with only bCPAP; it did not include other potential studies that had evaluated the effect of CPAP on reduction in the need of mechanical ventilation. 19, 27 Nurses can institute CPAP easily after 1 to 2 months of training and institution of CPAP has the potential to bring down the requirement and the cost of surfactant therapy. 15 This reduction has huge financial implications for LMIC.
The studies on safety of CPAP therapy suggested a very-low risk of pneumothorax (0 to 7.2%). When considering the lack of skilled manpower and the sub-optimal equipments available in most LMIC settings, the low risk is definitely reassuring. The recent systematic review on the efficacy and safety of bCPAP in LMIC settings also reported similar results. 39 We found a high risk of nasal trauma in neonates managed with CPAP. Up to 20% neonates developed nasal bleeding in one study. 34 This reinforces the need for good nursing care and monitoring. 15, 23, 25 With improving survival of very preterm neonates and need for longer duration of CPAP administration, nasal mucosal injury attains importance, given that it predisposes to immediate as well as long-term functional and cosmetic sequelae. 40 Implications for policy makers CPAP appears to be a promising and a safe technology for respiratory support in neonates with respiratory distress. In addition, due to lower initial costs, it has the potential for being up-scaled for management of respiratory distress in developing countries. But factors like cost and availability of consumables and additional equipment like humidifier and availability of skilled staff can limit the up-scaling of CPAP therapy. In addition, the use of CPAP also requires regular training of staff for optimal delivery of CPAP.
Strengths and weaknesses
Ours is possibly the first attempt to review and synthesize the available evidence on the effect of CPAP therapy on major outcomes including mortality and air leaks in preterm neonates. Given the paucity of randomized trials, we included observational studies so as to inform policy making. The studies in this review are limited by their study design and quality. We believe that CPAP is being widely used in LMICs than what is evident from the present review. Given the detailed search, the discrepancy is more to do with the 'real' paucity of studies from these settings. Possibly, the lack of resources, particularly the manpower, limits the capacity of health care providers from LMICs to publish their experiences in peer-reviewed journals.
CONCLUSION
Available evidence from observational studies suggests that CPAP is a safe and effective mode of therapy in preterm neonates with respiratory distress in LMIC. It reduces the in-hospital mortality and the need for ventilation thereby minimizing the need for uptransfer to a referral hospital. But given the overall paucity of studies and the low-quality evidence, there is an urgent need for high-quality studies on not only the safety and efficacy but also on the cost effectiveness of CPAP therapy in these settings.
